Product image of Lecigimon (Entacapone, Levodopa, Carbidopa Monohydrate) supplied by GNH India

Lecigimon

Active Ingredient:
Entacapone, Levodopa, Carbidopa Monohydrate
Origin:
EU

Lecigimon (Entacapone, Levodopa, Carbidopa Monohydrate)

Levodopa/Carbidopa/Entacapone, the active ingredient in Lecigimon, is a dopamine precursor with COMT inhibitor presented as an oral tablet formulation for intestinal use. It is indicated for the management of Parkinson's disease symptoms in adult patients. The combination enhances central dopamine availability while reducing peripheral metabolism, helping to control motor fluctuations.

GNH India supplies Lecigimon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Manufacturer / TM Owner

Lobsor Pharmaceuticals Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lecigimon, containing levodopa, carbidopa and entacapone, is used in the dopaminergic treatment pathway for Parkinson's disease.

  • Parkinson's disease: improves motor control and reduces OFF periods when used with levodopa.
  • Levodopa‑induced motor fluctuations: prolongs levodopa plasma half‑life to smooth symptom control.
  • Adjunct therapy in advanced Parkinsonian syndrome: helps maintain consistent dopaminergic stimulation and reduces dosing frequency.

How It Works

  • Levodopa is absorbed and crosses the blood‑brain barrier where it is decarboxylated to dopamine, replenishing deficient central dopamine. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, preventing premature conversion of levodopa and increasing its availability to the brain. Entacapone blocks catechol‑O‑methyltransferase (COMT) in peripheral tissues, slowing levodopa metabolism and extending its plasma half‑life, thereby providing more stable dopaminergic stimulation.

Side Effects

Lecigimon may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Dizziness: often related to orthostatic changes.
  • Insomnia: difficulty falling or staying asleep.
  • Hallucinations: visual or auditory disturbances, especially in older patients.
  • Orthostatic hypotension: drop in blood pressure upon standing.
  • Dry mouth: reduced salivation.

Serious or Rare Side Effects

  • Severe liver injury: elevated transaminases requiring monitoring.
  • Agranulocytosis: marked reduction in white blood cells.
  • Neuroleptic malignant syndrome: life‑threatening hyperthermia and rigidity.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Dyskinesia: involuntary movements with high dopaminergic exposure.
  • Hyperthermia: unexplained high fever requiring urgent care.

Precautions & Warnings

When prescribing Lecigimon, clinicians should consider several safety measures.

  • Monitor blood pressure: check for orthostatic hypotension, especially after dose initiation.
  • Assess hepatic function: obtain baseline liver enzymes and repeat periodically.
  • Evaluate psychiatric status: watch for new or worsening hallucinations or confusion.
  • Adjust dose in renal impairment: consider reduced dosing in patients with decreased clearance.
  • Avoid use in narrow‑angle glaucoma: the drug may increase intra‑ocular pressure.
  • Store at ambient temperature: keep below 25°C, protect from moisture and light.

Avoid Interactions

Lecigimon can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Non‑selective MAO inhibitors: risk of hypertensive crisis.
  • Anticholinergic agents: may worsen Parkinsonian symptoms.
  • CNS depressants: increased sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

  • SSRIs or SNRIs: potential for serotonin syndrome.
  • Diuretics: may enhance orthostatic hypotension.
  • Antihypertensive drugs: may require dose adjustment to avoid excessive blood pressure drop.

Frequently Asked Questions

Lecigimon is a prescription medication that combines levodopa, carbidopa and entacapone to treat Parkinson's disease. It is used to improve motor symptoms and reduce the frequency of OFF periods by enhancing and prolonging dopamine availability in the brain.

Levodopa is converted to dopamine in the brain, carbidopa blocks peripheral conversion of levodopa, and entacapone inhibits the COMT enzyme that breaks down levodopa. Together they increase central dopamine levels and extend its duration of action, providing more stable symptom control.

The specific dose of Lecigimon is individualized by the prescribing clinician based on the patient’s disease stage, response to therapy and tolerability. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Safety data for Lecigimon in pregnancy and lactation are limited. The medication should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Lecigimon, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lecigimon combines a dopamine precursor (levodopa) with a peripheral decarboxylase inhibitor (carbidopa) and a COMT inhibitor (entacapone). This triple combination offers more consistent dopamine levels compared with levodopa/carbidopa alone, reducing motor fluctuations without the need for separate COMT‑inhibitor tablets.

Lecigimon tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and light, and discard any tablets that appear discolored or damaged.

Lecigimon is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water and should be taken exactly as prescribed, without crushing or chewing unless specifically instructed by a healthcare professional.

Serious risks include severe liver injury, agranulocytosis, neuroleptic malignant syndrome, severe allergic reactions and dyskinesia. Patients should be monitored regularly for signs of hepatic dysfunction, blood‑cell abnormalities and any unexpected neurological or allergic symptoms.

Lecigimon is contraindicated in patients with known hypersensitivity to levodopa, carbidopa, entacapone or any excipients, as well as those taking non‑selective MAO inhibitors. Caution is also advised for individuals with narrow‑angle glaucoma, severe hepatic impairment or a history of serious cardiac arrhythmias.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Entacapone, Levodopa, Carbidopa Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT